ES2167370T3 - Activacion inmunologica a traves de una terapia intermitente con interleucina-2. - Google Patents

Activacion inmunologica a traves de una terapia intermitente con interleucina-2.

Info

Publication number
ES2167370T3
ES2167370T3 ES94920673T ES94920673T ES2167370T3 ES 2167370 T3 ES2167370 T3 ES 2167370T3 ES 94920673 T ES94920673 T ES 94920673T ES 94920673 T ES94920673 T ES 94920673T ES 2167370 T3 ES2167370 T3 ES 2167370T3
Authority
ES
Spain
Prior art keywords
therapy
period
interleucine
infusions
intermittent therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94920673T
Other languages
English (en)
Inventor
H Clifford Lane
Joseph A Kovacs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of ES2167370T3 publication Critical patent/ES2167370T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

UN METODO PARA ACTIVAR EL SISTEMA INMUNE DE UN MAMIFERO CONLLEVA UNA SERIE DE INFUSIONES DE IL-2 CONTINUAS QUE SON EFECTUADAS DE FORMA INTERMITENTE DURANTE UN PERIODO EXTENDIDO. POR EJEMPLO, IL-2 PUEDE SER ADMINISTRADA CONTINUAMENTE DURANTE UN PERIODO QUE ESTE EN EL ORDEN DE 5 DIAS, E INFUSIONES SUCESIVAS DE ESTA NATURALEZA PUEDEN SER SEPARADAS POR UN PERIODO DE AL MENOS 4 SEMANAS. LOS EFECTOS BENEFICIOSOS EXPERIMENTADOS, INCLUYENDO CUENTAS DE CELULAS CD4 ELEVADAS, RESTAURACION DE LA FUNCION LINFOCITICA Y UN AUMENTO DEL NUMERO DE RECEPTORES DE IL2, SE LOGRAN CON TAL TERAPIA INTERMITENTE DE IL-2, QUE PUEDE SER COMBINADA CON OTRA TERAPIA CUYO OBJETIVO SEA UN ESTADO DE ENFERMEDAD ESPECIFICO, COMO UNA TERAPIA ANTI-RETROVIRAL QUE COMPRENDA, POR EJEMPLO, LA ADMINISTRACION DE AZT, DDI O INTERFERONA ALFA. ADEMAS, LA ADMINISTRACION DE IL-2 PUEDE EMPLEARSE PARA FACILITAR LA TRANSDUCCION DE CELULAS T IN SITU EN EL CONTEXTO DE TERAPIA DE GENES. MEDIANTE ESTE METODO LAS CELULAS SON EN PRIMER LUGAR ACTIVADAS IN VIVO A TRAVES DE LA TERAPIA DE IL-2 ANTERIORMENTE MENCIONADA, Y LA TRANSDUCCION ES ENTONCES EFECTUADA MEDIANTE LA DISTRIBUCION DE UN VECTOR RETROVIRAL MANIPULADO GENETICAMENTE DIRECTAMENTE AL PACIENTE.
ES94920673T 1993-05-19 1994-05-19 Activacion inmunologica a traves de una terapia intermitente con interleucina-2. Expired - Lifetime ES2167370T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/063,315 US5419900A (en) 1993-05-19 1993-05-19 Immunologic enhancement with intermittent interleukin-2 therapy

Publications (1)

Publication Number Publication Date
ES2167370T3 true ES2167370T3 (es) 2002-05-16

Family

ID=22048393

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94920673T Expired - Lifetime ES2167370T3 (es) 1993-05-19 1994-05-19 Activacion inmunologica a traves de una terapia intermitente con interleucina-2.

Country Status (11)

Country Link
US (3) US5419900A (es)
EP (1) EP0702560B1 (es)
JP (1) JP4275193B2 (es)
AT (1) ATE208206T1 (es)
AU (1) AU691504B2 (es)
CA (1) CA2163219A1 (es)
DE (1) DE69428992T2 (es)
DK (1) DK0702560T3 (es)
ES (1) ES2167370T3 (es)
PT (1) PT702560E (es)
WO (1) WO1994026293A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696079A (en) * 1993-05-19 1997-12-09 The United States Of America As Represented By The Department Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US5419900A (en) * 1993-05-19 1995-05-30 The United States Of America As Represented By The Department Of Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
JP2002515730A (ja) * 1995-10-16 2002-05-28 カイロン コーポレイション 遺伝子発現を変調する因子のスクリーニング方法
KR100220645B1 (ko) * 1997-07-04 1999-09-15 구광시 벤젠유도체의 제조방법
US6498006B2 (en) * 1997-11-24 2002-12-24 Johnson T. Wong Methods for treatment of HIV and other infections using A T cell or viral activator and anti-retroviral combination therapy
AU2221600A (en) * 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
DK1141315T3 (da) 1998-12-31 2008-05-19 Novartis Vaccines & Diagnostic Modificerede HIV Env-polypeptider
US6921530B1 (en) * 1999-09-24 2005-07-26 Cornell Research Foundation, Inc. Low dose IL-2 for potentiation of immunity
CA2421409A1 (fr) * 2000-09-08 2002-03-14 Aventis Pasteur Utilisation de lipopeptides pour l'immunotherapie des sujets vih+
FR2813793B1 (fr) * 2000-09-08 2003-01-24 Aventis Pasteur Utilisation de lipopeptides pour l'immunotherapie des sujets vih+
US6579521B2 (en) * 2000-10-20 2003-06-17 Chiron Corporation Methods of therapy for HIV infection
US20030003074A1 (en) * 2001-06-14 2003-01-02 Macromed, Inc. Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
US20060159657A1 (en) * 2001-06-14 2006-07-20 Macromed, Incorporated Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
WO2003004620A2 (en) 2001-07-05 2003-01-16 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030198621A1 (en) * 2001-07-05 2003-10-23 Megede Jan Zur Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
AU2002355955A1 (en) * 2001-08-13 2003-03-03 University Of Southern California Interleukin-2 mutants with reduced toxicity
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
EP1427806A4 (en) * 2001-08-31 2006-04-26 Chiron Corp ANTIGENIC HIV-TYPE B POLYPEPTIDE-CODING POLYNUCLEOTIDES, POLYPEPTIDES, AND USES THEREOF
RU2201762C1 (ru) * 2001-10-09 2003-04-10 Свадовский Александр Игоревич Способ лечения внутримозговой опухоли головного мозга
JP5015601B2 (ja) 2003-10-21 2012-08-29 セダーズ−シナイ メディカル センター 中枢神経系の癌を含む癌の処置のための系および方法
US20070098685A1 (en) * 2005-01-19 2007-05-03 Brand Stephen J Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist
US8129184B2 (en) 2006-09-26 2012-03-06 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008039974A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
WO2010028066A2 (en) 2008-09-02 2010-03-11 Cedars-Sinai Medical Center Cd133 epitopes
ES2618573T3 (es) 2009-05-07 2017-06-21 ImmunoCellular Therapeutics,Ltd Epítopos de CD133
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
WO2013033626A2 (en) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
ES2719495T3 (es) 2012-05-07 2019-07-10 Dartmouth College Anticuerpo dirigido contra b7-h6, proteínas de fusión, y métodos de uso de los mismos
EP2956544B1 (en) 2013-02-14 2017-11-01 Immunocellular Therapeutics Ltd. Cancer vaccines and vaccination methods
CA2963602A1 (en) 2014-10-09 2016-04-14 Dana-Farber Cancer Institute, Inc. Multiple-variable il-2 dose regimen for treating immune disorders
AU2018372167B2 (en) 2017-11-21 2023-12-07 The Board Of Trustees Of The Leland Stanford Junior University Partial agonists of interleukin-2
JP7303391B2 (ja) 2020-01-14 2023-07-04 シンセカイン インコーポレイテッド バイアス型ｉｌ２ムテイン、方法、および組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4908433A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Uses of interleukin-2
US4863730A (en) 1986-03-21 1989-09-05 Cenfold Holdings, S.A. Immunotherapy for AIDS patients
US4868157A (en) 1987-10-05 1989-09-19 Merck & Co., Inc. Dipeptidyl 2-amino-1,2-dideoxy-D-glucose derivatives as host resistance enhancers in AIDS-immunocompromised hosts and methods of use
US4866157A (en) * 1987-11-10 1989-09-12 Sugio Otani Thermosetting aromatic resin composition
DE3818054C2 (de) * 1988-05-27 1994-02-17 Biotest Pharma Gmbh Verwendung einer Kombination aus einem Antigen bzw. einer Vakzine und humanem Interleukin zur Behandlung der Non-Responsiveness gegenüber immunologischen Defektzuständen
FR2653020B1 (fr) * 1989-10-17 1993-03-26 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour la preparation de compositions pharmaceutiques destinees au traitement des leucemies.
US5026687A (en) * 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
ES2134294T3 (es) 1990-01-26 1999-10-01 Washington Res Found Reactividad inmune para oncogenes expresados activos para la diagnosis y el tratamiento de tumores malignos.
FR2660863B1 (fr) * 1990-04-17 1994-01-21 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement de cancers primitifs de la plevre.
US5696079A (en) 1993-05-19 1997-12-09 The United States Of America As Represented By The Department Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US5419900A (en) 1993-05-19 1995-05-30 The United States Of America As Represented By The Department Of Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy

Also Published As

Publication number Publication date
DE69428992D1 (de) 2001-12-13
JPH09500362A (ja) 1997-01-14
DE69428992T2 (de) 2002-08-14
ATE208206T1 (de) 2001-11-15
AU691504B2 (en) 1998-05-21
US6548055B1 (en) 2003-04-15
EP0702560B1 (en) 2001-11-07
AU7137794A (en) 1994-12-12
US6190656B1 (en) 2001-02-20
EP0702560A1 (en) 1996-03-27
US5419900A (en) 1995-05-30
CA2163219A1 (en) 1994-11-24
WO1994026293A1 (en) 1994-11-24
DK0702560T3 (da) 2002-02-25
PT702560E (pt) 2002-04-29
JP4275193B2 (ja) 2009-06-10

Similar Documents

Publication Publication Date Title
ES2167370T3 (es) Activacion inmunologica a traves de una terapia intermitente con interleucina-2.
ES2156852T3 (es) Citoquina mamifera, il-11.
MY103212A (en) Zinc-protamine-alpha interferon complex
DE69333580D1 (de) Immunregulation über die cd28-route
YU61502A (sh) Nukleozidni analozi karboksamidno modifikovanih bicikličnih baza
DK0626177T3 (da) Ernæring til personer inficeret med humant immundefekt-virus
FI924082A (fi) Idiotypvaccination mot b-cellymfoma
ATE66613T1 (de) Immunstimulierende mittel.
AU621830B2 (en) Method and dosage form using an antagonist to gamma interferon to control mhc-associated autoimmune disease
KR950702120A (ko) 골다공증 치료를 위한 포스포네이트의 용도(use of phosphonates for the treatment of osteoporosis)
EP0282343A3 (en) Method to stimulate the immune response to specific antigens
CA2063721A1 (fr) Medicament immunostimulant a base de glycopeptidolipides polaires de mycobacterium chelonae
IT1232819B (it) Impiego di sorgenti di nucleobasi per stimolare la funzione immunitaria, relativo procedimento e composizioni farmaceutiche contenenti una tale sorgente di nucleobasi
RU94045248A (ru) Способ ингибирования активности вируса иммунодефицита человека (hiv) in vivo
ATE84221T1 (de) Arzneimittel mit methylcellulose.
IT1237435B (it) Farmaco attivo nel ripristino della plasticita' neuronale.
Lein Immune-based therapies
Lane et al. Immunologic enhancement with intermittent interleukin-2 therapy
Grodeck IL-2 restores immune sytem
RU95104171A (ru) Средство для лечения иммуносупрессии при сепсисе у человека и способ ее лечения
Whiteside The natural killer (NK) cell and synergistic antitumor effects of interferon-gamma and interleukin-2
MY106292A (en) (alpha)-adrenergic receptor antagonists.
DK0592476T3 (da) Anvendelse af interleukin 10 til fremstilling af lægemidler med tumorhæmmende virkning
杨贵贞 et al. EFFECTS OF GINSENOSIDE ON THE NATURAL KILLER CELL-INTERFERON-INTERLEUKIN-2 REGULATORY NETWORK AND ITS TUMOR INHIBITING EFFECT
BG102182A (en) The use of ipriflavon for reducing the number of cd8+ cells